Investor Presentaiton

Six strategic priorities ☑ EXPAND THE GLP-1 MARKET AND WIN WITH SEMAGLUTIDE DRIVE INSULIN VOLUME AND VALUE SHARE BUILD THE GLOBAL OBESITY MARKET Investor Presentation First nine months of 2018 Slide 32 E RETURN TO GROWTH IN BIOPHARM 7 DRIVE COMMERCIAL INNOVATION INNOVATE AND EXPAND PATIENT BASE novo nordisk

View entire presentation